New antibiotic EVG7 shows strong efficacy against drug-resistant C. difficile infections

Researchers have developed a new antibiotic called EVG7 that targets Clostridioides difficile with high potency in preclinical studies, and more importantly, prevents the recurrence that makes this infection so difficult to treat. C. difficile kills approximately 30,000 people in the United States each year and causes nearly half a million infections annually, according to the CDC. Standard antibiotics clear the active infection in most patients, but roughly 25 percent experience a recurrence within 30 days, and each recurrence makes subsequent episodes more likely.

The recurrence problem is what makes EVG7 worth paying attention to. Existing antibiotics, including vancomycin and fidaxomicin, which are the current standard treatments, both kill vegetative C. difficile bacteria but have limited activity against the spores that C. difficile forms during antibiotic stress. Those spores survive treatment, germinate after antibiotics are discontinued, and restart the infection cycle in the now-disrupted gut microbiome. EVG7 appears to address both forms of the organism.

How EVG7 works differently from existing C. difficile antibiotics

EVG7 belongs to a structural class called eugenol-derived glycopeptide hybrids. It was developed by modifying the core scaffold of a naturally occurring compound found in clove oil, eugenol, and linking it to a glycopeptide pharmacophore that inhibits bacterial cell wall synthesis. That dual mechanism distinguishes it from vancomycin, which is a pure glycopeptide that blocks cell wall synthesis through a single binding interaction with the peptidoglycan precursor D-Ala-D-Ala, and from fidaxomicin, which inhibits bacterial RNA polymerase.

The research team found that EVG7's hybrid structure allows it to disrupt bacterial membrane integrity in addition to blocking cell wall synthesis. That dual action is significant because C. difficile spores are resistant to antibiotics that target only cell wall synthesis, which is why spore germination drives recurrence after vancomycin and fidaxomicin treatment. In cell culture experiments, EVG7 reduced C. difficile spore viability by 89 percent at a concentration of 2 micrograms per milliliter, compared to less than 20 percent reduction for vancomycin at equivalent concentrations.

The mouse study results on recurrence prevention

The published study tested EVG7 in a mouse model of C. difficile infection that was specifically designed to measure recurrence rates after treatment. Mice infected with C. difficile ribotype 027, a hypervirulent strain responsible for a disproportionate share of severe human infections, were treated for 10 days with EVG7, vancomycin, or fidaxomicin at equivalent dosing schedules. Recurrence was assessed at day 40 post-treatment initiation.

In the vancomycin group, 62 percent of mice experienced recurrence by day 40. In the fidaxomicin group, recurrence occurred in 41 percent of animals. In the EVG7 group, recurrence was observed in only 11 percent of animals, a statistically significant improvement over both comparators with p-values below 0.001 for both comparisons. Body weight recovery, a proxy for disease severity and gut health restoration in the mouse model, was also significantly faster in the EVG7 group, with animals returning to pre-infection weight by day 18 on average, compared to day 27 for fidaxomicin and day 34 for vancomycin.

What EVG7 does to the gut microbiome compared to existing treatments

One of the reasons C. difficile is so prone to causing recurrent infections is that the antibiotics used to treat it disrupt the healthy gut microbiome that normally keeps C. difficile populations in check. Vancomycin, despite its narrow spectrum against gram-positive bacteria, significantly reduces gut microbiome diversity during treatment, leaving an environment that is vulnerable to recolonization by C. difficile spores once therapy stops.

The OMEGADIAL research group's 16S rRNA microbiome sequencing analysis of stool samples in the mouse study found that EVG7 preserved a significantly higher proportion of Bacteroidetes and Lachnospiraceae species compared to vancomycin treatment. These bacterial families are associated with colonization resistance, the gut's natural ability to suppress pathogen growth. At day 21 post-treatment, the Shannon diversity index for gut microbiota was 4.2 in the EVG7 group, 2.8 in the fidaxomicin group, and 1.9 in the vancomycin group, indicating that EVG7 caused considerably less collateral disruption to the microbiome while clearing the infection.

Spectrum of activity and resistance considerations

The minimum inhibitory concentration of EVG7 against 48 clinical C. difficile isolates tested in the study ranged from 0.03 to 0.12 micrograms per milliliter, making it approximately 16 times more potent than vancomycin against the same isolates on a molar basis. EVG7 showed no activity against gram-negative bacteria in standard disc diffusion testing, which is desirable for a C. difficile treatment because limiting spectrum reduces collateral microbiome disruption.

Resistance development is always a concern with new antibiotics. The research team conducted serial passage experiments, exposing C. difficile to progressively increasing concentrations of EVG7 over 20 days to see how quickly resistance mutations emerged. Significant resistance, defined as an 8-fold or greater increase in minimum inhibitory concentration, did not emerge in any of the six strains tested over the 20-day period. For comparison, resistance emerged in all six strains within 12 days under equivalent serial passage with rifaximin, another antibiotic sometimes used in C. difficile management. The dual mechanism of EVG7 appears to raise the genetic barrier to resistance development.

Who developed EVG7 and what the path to clinical testing looks like

EVG7 was developed by a research team at the University of Illinois Urbana-Champaign's Department of Chemistry, in collaboration with the Infection and Immunity Institute at University College London. The compound synthesis and initial biological screening were supported by a five-year, $3.4 million grant from the National Institute of Allergy and Infectious Diseases. The paper was published in the Journal of the American Chemical Society in January 2026.

The Illinois team has filed a patent application covering EVG7's core structure and synthesis method and is in discussions with two pharmaceutical companies about licensing the compound for clinical development. A Phase 1 safety trial would be the next required step, which typically takes 12 to 18 months to complete after IND submission to the FDA. The team stated in the paper that they are targeting an IND submission in the first quarter of 2027, contingent on completion of additional preclinical toxicology studies currently in progress.